At the Far End of the Spectrum: Ten-Year Data on the Duodenal Switch Family

When bariatric surgery reaches the news, it usually arrives as a choice between two names: the sleeve and the bypass. There is a third family of operations, far less common, that has always posted the largest figures on both sides of the ledger — the greatest weight loss and the most complete diabetes remission, and the heaviest long-term nutritional bill.

Its members share one mechanism. Biliopancreatic diversion (BPD), described by Nicola Scopinaro in the 1970s, separates bile and pancreatic enzymes from food for most of the small intestine. Biliopancreatic diversion with duodenal switch (BPD-DS) adds a sleeve-shaped stomach and a duodenal anastomosis. SADI-S, the newest variant, replaces the switch with a single duodeno-ileal anastomosis above a sleeve. In every case the point is a deliberately shortened common channel — the last stretch of bowel where digestive enzymes finally meet the meal and fat is absorbed. The trade-off is built into the design, not into the patient.

A cluster of studies published in the past three weeks has put that trade-off under unusually close scrutiny: a national registry comparison at six months, a meta-analysis reaching past ten years, a single randomized trial, and a systematic review that quietly demonstrates how thin the comparative evidence still is.

The registry view: 116,195 operations, six months later

The largest of the new datasets comes from the 2023 MBSAQIP database, the American College of Surgeons quality registry that captures most US bariatric operations. A Johns Hopkins–led team compared six-month outcomes across four procedures after 1:1 propensity-score matching on 47 variables, a design that attempts to make observational groups look alike on the things clinicians already know about them. The matched cohort held 80,614 sleeves, 33,148 Roux-en-Y gastric bypasses, 1,518 BPD-DS and 915 SADI-S operations.

Bypass beat sleeve on every metabolic endpoint the authors measured — diabetes remission 64.1% versus 58.1%, hypertension 41.9% versus 35.8%, hyperlipidemia 43.0% versus 37.1%, and reflux remission 55.6% versus 44.9%, alongside greater excess-weight loss. But BPD-DS outdistanced both: 52.4% excess-weight loss against 37.7% for sleeve and 45.9% for bypass, and diabetes remission of 73.3% against 59.9% and 65.6%. SADI-S tracked bypass closely, with no significant difference in excess-weight loss (44.99% versus 44.73%). Registry analysis at six months cannot speak to durability or to late deficiencies, but it does establish that the duodenal switch family is not merely surgical trivia: it is what roughly one in fifty American bariatric operations now is.

Ten years and 22 study cohorts

Durability is where the anchor paper lands. A meta-analysis in Obesity Surgery pooled 22 studies and 2,156 patients followed at least a decade after BPD or BPD-DS. Mean BMI fell by 19.02 kg/m². For BPD-DS, total weight loss reached 36.34% and excess-weight loss 75.22%. Diabetes resolved in 78% of patients, hyperlipidemia in 83%, obstructive sleep apnea in 89% and hypertension in 63%. Against Roux-en-Y bypass, the diversion procedures showed a further BMI reduction of 6.31 kg/m² (95% CI 3.16–9.47) and roughly triple the odds of diabetes resolution (OR 3.49, 95% CI 1.11–10.91), at the cost of more cholecystectomies.

Then the other column. Revision surgery was required in 3% of patients. Anemia affected 19%, iron deficiency 34% and bone disorders 25%; diabetes relapsed in 15%. These are the same late nutritional consequences explored in three recent papers on bone density, trace minerals and anemia after metabolic surgery — but arriving at higher frequency, which is what a shortened absorbing channel predicts. Evidence here is a systematic review of mostly observational cohorts, not randomized comparison, and pooled proportions from heterogeneous long-term series deserve exactly that caveat.

One randomized trial, ninety patients

The newest member of the family has the least long-term data and, so far, the best-designed single study. The OASIS trial in Barcelona randomized 90 patients with BMI 45–50 to either SADI-S or one-anastomosis gastric bypass and followed them for a year — a randomized, single-blind comparison, though from a single centre and with a small sample. Weight outcomes were statistically indistinguishable: excess-weight loss 84.34% versus 79.61%, total weight loss 35.85% versus 33.02%, with no significant gap in comorbidity resolution or quality of life. Nutritional deficiencies were uncommon in both arms (7.3% versus 4.3%) and were all iron-related.

The separation appeared in complications after 30 days: 7.1% after SADI-S against 35.4% after one-anastomosis bypass, driven mainly by bile reflux managed conservatively or endoscopically. Yet SADI-S produced fewer but more severe events, including two reoperations for nutritional complications and one death not attributed to the procedure. Single-centre randomized data at one year is a genuinely higher evidence tier than a registry, and also a much narrower window.

Where the evidence still thins out

For patients weighing SADI-S against the standard bypass, the honest answer is that nobody has run the trial that would settle it. A systematic review of 12 comparative studies and 3,317 patients found a possible weight-loss advantage for SADI-S at selected time points, no clear difference in diabetes, hypertension or lipid remission, and a suggestion of fewer late surgical complications — with calcium deficiency trending the other way. The authors graded the certainty of evidence low to very low, and noted that no included study supplied mortality data suitable for pooling.

That gap is characteristic of the field’s most invasive procedures: performed too rarely to power a trial, followed too inconsistently to answer the durability question cleanly. The prospective cohort model that produced the best long-horizon bariatric data — the LABS study, funded by NIDDK and documented in this archive — enrolled these operations only in small numbers, and this site remains an independent observatory rather than a voice for any agency or society. For now, the duodenal switch family offers the strongest metabolic results in bariatric surgery and, on the published record, the most demanding follow-up. Both halves of that sentence are the finding.